The Next Blockbuster – You Decide!
CNN Money reports that "After a rough couple of years dealing with patent expirations and the often frustrating hunt for new products, drug industry...
Disease Mongering Podcast
MP3 Audio File for your iPODWMA Audio File for Windows Media Player and other audio playersWAX Audio File for Windows Media PlayerNever heard...
DTC Set to Surpass DTPhysician
The November GAO report on FDA's Oversight of Direct-to-Consumer (DTC) advertising, which I mentioned in yesterday's post (see "Where's DDMAC's Head At?"), includes data...
Where’s DDMAC’s Head At?
At the recent Healthcare Blogging Summit (see "Physician Blogging - Survey Results"), an audience member asked the following question:How is DDMAC likely to regulate...
Merck on a Roll
Merck is on a roll these days.For one thing, it's stock price has almost recovered from its low point after Vioxx was withdrawn from...
Celebrex Joins the bAdWord Bandwagon!
Just when I thought it was safe to stop raking Pfizer over the coals about torcetrapib, they go and do something stupid! I'm talking...
Physician Blogging – Survey Results
Yesterday, I participated in a panel discussion at the first Healthcare Blogging Summit, which was co-located with the larger Consumer Health World conference in...
Tufts Hangs Tough on Opportunity Cost Analysis
Last week I questioned the $800 million quoted in the press and other blogs as the cost of Pfizer's torcetrapib failure (see torcetrapib: "$800...
Is Pfizer Arrogant and Superior?
The members of the online Pharma Marketing Discussion Board, which I moderate, had a lively exchange on the subject of Pfizer, torcetrapib, and drug...
Betting the Pharm
Pfizer's failure to launch torcetrapib will have repercussions throughout the industry on many different levels. As a seminal event, it will rival the withdrawal...
